Patrick Lin Biography and Net Worth

Insider of Heatwurx

Mr. Lin has over 20 years of financing and investing experience in the Biopharm Sector. He was Co-Founder and Chairman of the Board of Promet Therapeutics, LLC . He is Founder and Managing Partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co. Mr. Lin was Co-Founding Partner of E*Offering.

Mr. Lin received an MBA from Kellogg Graduate School of Management, a Master of Engineering Management, and a Bachelor of Science in Business Administration from the University of Southern California.

What is Patrick Lin's net worth?: The estimated net worth of Patrick Lin is at least $7.05 thousand as of January 31st, 2024. Mr. Lin owns 25,978 shares of Heatwurx stock worth more than $7,045 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Lin may own. Additionally, Mr. Lin receives a salary of $117,150.00 as Insider at Heatwurx. Learn More about Patrick Lin's net worth.
How old is Patrick Lin?: Mr. Lin is currently 59 years old. There are 5 older executives and no younger executives at Heatwurx. The oldest executive at Heatwurx is Dr. David Young Ph.D., Pharm.D., Co-Founder, President of Research and Development & Director, who is 71 years old. Learn More on Patrick Lin's age.
What is Patrick Lin's salary?: As the Insider of Heatwurx Inc., Mr. Lin earns $117,150.00 per year. There are 4 executives that earn more than Mr. Lin. The highest earning executive at Heatwurx is Mr. George K. Ng Esq., J.D., CEO & Director, who commands a salary of $402,030.00 per year. Learn More on Patrick Lin's salary.
How do I contact Patrick Lin?: The corporate mailing address for Mr. Lin and other Heatwurx executives is 7380 COCA COLA DRIVE SUITE 106, HANOVER MD, 21076. Heatwurx can also be reached via phone at (443) 776-3133 and via email at [email protected]. Learn More on Patrick Lin's contact information.
Has Patrick Lin been buying or selling shares of Heatwurx?: Patrick Lin has not been actively trading shares of Heatwurx during the last quarter. Most recently, on Wednesday, January 31st, Patrick Lin bought 2,500 shares of Heatwurx stock. The stock was acquired at an average cost of $2.37 per share, with a total value of $5,925.00. Following the completion of the transaction, the insider now directly owns 25,978 shares of the company's stock, valued at $61,567.86. Learn More on Patrick Lin's trading history.
Who are Heatwurx's active insiders?: Heatwurx's insider roster includes Robert Floyd (COO), Patrick Lin (Insider), James Stanker (CFO), Justin Yorke (Director), and David Young (CEO). Learn More on Heatwurx's active insiders.
Are insiders buying or selling shares of Heatwurx?: During the last year, Heatwurx insiders bought shares 3 times. They purchased a total of 224,100 shares worth more than $179,280.00. The most recent insider tranaction occured on January, 27th when CEO George K Ng bought 87,200 shares worth more than $69,760.00. Insiders at Heatwurx own 2.4% of the company. Learn More about insider trades at Heatwurx.
Information on this page was last updated on 1/27/2025.

Patrick Lin Insider Trading History at Heatwurx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2024	Buy	2,500	$2.37	$5,925.00	25,978
5/17/2022	Buy	100	$31.80	$3,180.00	21,669
4/6/2022	Buy	60	$62.60	$3,756.00	21,569
12/14/2021	Buy	150	$80.00	$12,000.00
12/3/2021	Buy	175	$96.00	$16,800.00
8/26/2021	Buy	200	$120.40	$24,080.00	21,144

Patrick Lin Buying and Selling Activity at Heatwurx

Heatwurx Company Overview

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Today's Range

Now: $0.27

$0.26

$0.29

50 Day Range

MA: $0.31

$0.19

$0.48

2 Week Range

Now: $0.27

$0.15

$1.50

Volume

1,515,478 shs

Average Volume

1,286,689 shs

Market Capitalization

$15.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Patrick Lin Biography and Net Worth

What is Patrick Lin's net worth?

How old is Patrick Lin?

What is Patrick Lin's salary?

How do I contact Patrick Lin?

Has Patrick Lin been buying or selling shares of Heatwurx?

Who are Heatwurx's active insiders?

Are insiders buying or selling shares of Heatwurx?